AdvanCell
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $112M
Overview
A biotech developing targeted alpha-particle therapies for precise cancer treatment.
OncologyDiagnostics
Technology Platform
A proprietary platform for conjugating alpha-emitting radioisotopes (e.g., Actinium-225) to tumor-targeting antibodies and small molecules to create targeted radiopharmaceuticals.
Funding History
1Total raised:$112M
Series B$112M
Opportunities
Capitalizing on the high unmet need in advanced prostate cancer and the expanding validation of radiopharmaceuticals as a major oncology modality.
Risk Factors
Heavily dependent on securing a reliable and scalable supply of rare and expensive alpha-emitting radioisotopes like Actinium-225.
Competitive Landscape
Competes in the targeted radiopharmaceutical space against large pharma (Novartis, Bayer) and biotechs like Fusion Pharmaceuticals and RayzeBio, focusing on the niche but potent alpha-therapy segment.